menu

COVID-19 and HCV Risk: Anticipating the Impact of the Pandemic on Vulnerable Populations

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Hot Topics in HCV: A Multidisciplinary Online Minicurriculum - Activity 3: Anticipating the Impact of the COVID-19 Pandemic on Vulnerable Populations

close
0.25 credits
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    The COVID-19 pandemic has taken a disproportional toll on already vulnerable persons, yet substance use, psychosocial comorbidities, and preexisting disparities in access to care may translate to an even greater adverse impact among persons with chronic HCV. This educational activity offers up-to-date information on the impact of COVID-19 on the normal and HCV-infected liver, practical strategies for optimizing telehealth-delivered HCV care, and other recommendations for engaging vulnerable populations in HCV care during times of reduced service capacity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

    This activity is jointly provided by Global Education Group and Integritas Communications.

  • Commercial Support

    This activity is supported by an educational grant from AbbVie Inc.

  • References

    1. American Association for the Study of Liver Diseases (AASLD). COVID-19 and the liver. https://www.aasld.org/about-aasld/covid-19-and-liver. Accessed July 5, 2021. 
    2. Kaufman HW, et al. Decreases in hepatitis C testing and treatment during the COVID-19 pandemic. Am J Prev Med. 2021 (Epub ahead of print).
    3. Valdiserri RO, et al. The uses of adversity: leveraging the COVID-19 response to eliminate viral hepatitis. Health Affairs Blog. 2020. https://www.healthaffairs.org/do/10.1377/hblog20200624.84875/full/. Accessed July 5, 2021.
  • Target Audience

    The educational design of this activity addresses the needs of infectious diseases specialists, hepatologists, gastroenterologists, and other clinicians potentially involved in screening, counseling, or treatment of hepatitis C virus (HCV).

  • Educational Objective

    After completing this activity, the participant should be better able to:

    • Describe the impact of COVID-19 on the HCV-infected liver and on access to care among vulnerable populations
  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

    Physician Credit Designation
    Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Nursing Continuing Education
    Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

    This educational activity for 0.25 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Instructions to Receive Credit

    In order to receive credit for this activity, the participant must review the activity as well as successfully complete the posttest and evaluation form.

  • Term of Offering

    This activity was released on September 30, 2021 and is valid for one year. Requests for credit must be made no later than September 30, 2022.

  • Global Contact Information

    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

  • System Requirements

    PC
    1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
    Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
    512 MB of RAM (1 GB recommended)
    Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
    For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above) 

    MAC
    1.83 GHz Intel Core Duo or faster processor
    512 MB of RAM (1 GB recommended)
    MAC OS X 10.12, 10.13 and 10.14
    Mozilla Firefox, Apple Safari, Google Chrome
    For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

  • Fee Information & Refund/Cancellation Policy

    There is no fee for this educational activity.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest
    Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

    All relevant financial relationships have been mitigated.

    The faculty have the following relevant financial relationships with ineligible companies:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Ricardo Franco, MD

    Consulting Fees: Theratechnologies Inc.

    Contracted Research: AbbVie Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc.

    David L. Wyles, MD

    Contracted Research: Gilead Sciences, Inc.

    The planners and managers have the following relevant financial relationships with ineligible companies:

    Name of Planner or Manager

    Reported Financial Relationship

    Rhys Williams, RN, MSN, FNP

    Nothing to disclose

    Lindsay Borvansky

    Nothing to disclose

    Andrea Funk

    Nothing to disclose

    Liddy Knight

    Nothing to disclose

    Ashley Cann

    Nothing to disclose

    Jeanette Ruby, MD

    Nothing to disclose

    Jim Kappler, PhD

    Nothing to disclose

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The COVID-19 pandemic has taken a disproportional toll on already vulnerable persons, yet substance use, psychosocial comorbidities, and preexisting disparities in access to care may translate to an even greater adverse impact among persons with chronic HCV. This educational activity offers up-to-date information on the impact of COVID-19 on the normal and HCV-infected liver, practical strategies for optimizing telehealth-delivered HCV care, and other recommendations for engaging vulnerable populations in HCV care during times of reduced service capacity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

    This activity is jointly provided by Global Education Group and Integritas Communications.

  • Commercial Support

    This activity is supported by an educational grant from AbbVie Inc.

  • References

    1. American Association for the Study of Liver Diseases (AASLD). COVID-19 and the liver. https://www.aasld.org/about-aasld/covid-19-and-liver. Accessed July 5, 2021. 
    2. Kaufman HW, et al. Decreases in hepatitis C testing and treatment during the COVID-19 pandemic. Am J Prev Med. 2021 (Epub ahead of print).
    3. Valdiserri RO, et al. The uses of adversity: leveraging the COVID-19 response to eliminate viral hepatitis. Health Affairs Blog. 2020. https://www.healthaffairs.org/do/10.1377/hblog20200624.84875/full/. Accessed July 5, 2021.
  • Target Audience

    The educational design of this activity addresses the needs of infectious diseases specialists, hepatologists, gastroenterologists, and other clinicians potentially involved in screening, counseling, or treatment of hepatitis C virus (HCV).

  • Educational Objective

    After completing this activity, the participant should be better able to:

    • Describe the impact of COVID-19 on the HCV-infected liver and on access to care among vulnerable populations
  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

    Physician Credit Designation
    Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Nursing Continuing Education
    Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

    This educational activity for 0.25 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Instructions to Receive Credit

    In order to receive credit for this activity, the participant must review the activity as well as successfully complete the posttest and evaluation form.

  • Term of Offering

    This activity was released on September 30, 2021 and is valid for one year. Requests for credit must be made no later than September 30, 2022.

  • Global Contact Information

    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

  • System Requirements

    PC
    1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
    Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
    512 MB of RAM (1 GB recommended)
    Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
    For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above) 

    MAC
    1.83 GHz Intel Core Duo or faster processor
    512 MB of RAM (1 GB recommended)
    MAC OS X 10.12, 10.13 and 10.14
    Mozilla Firefox, Apple Safari, Google Chrome
    For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

  • Fee Information & Refund/Cancellation Policy

    There is no fee for this educational activity.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest
    Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

    All relevant financial relationships have been mitigated.

    The faculty have the following relevant financial relationships with ineligible companies:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Ricardo Franco, MD

    Consulting Fees: Theratechnologies Inc.

    Contracted Research: AbbVie Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc.

    David L. Wyles, MD

    Contracted Research: Gilead Sciences, Inc.

    The planners and managers have the following relevant financial relationships with ineligible companies:

    Name of Planner or Manager

    Reported Financial Relationship

    Rhys Williams, RN, MSN, FNP

    Nothing to disclose

    Lindsay Borvansky

    Nothing to disclose

    Andrea Funk

    Nothing to disclose

    Liddy Knight

    Nothing to disclose

    Ashley Cann

    Nothing to disclose

    Jeanette Ruby, MD

    Nothing to disclose

    Jim Kappler, PhD

    Nothing to disclose

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule21 Oct 2021
Webpack App